{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:09:24Z","timestamp":1789556964973,"version":"build-2803163510"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a complex autoimmune disease often characterised by dysregulated immune responses to self-DNA. Emerging evidence highlights the role of cell-free DNA (cfDNA) in promoting immune activation in SLE. Cell-free DNA is released primarily during cell death and is cleared by nucleases such as DNASE1L3. This review explores how molecular characteristics of cfDNA, such as fragment length, end motifs, jaggedness, and epigenetic modifications, serve as biomarkers of disease activity and may contribute to pathogenesis. The review then explains how deficiencies in DNASE1L3 alter cfDNA fragmentation, increase immunogenic potential, and enhance type I interferon signalling via plasmacytoid dendritic cells, driving B-cell differentiation and anti-double-stranded DNA (anti-dsDNA) antibody production. We also discuss how autoantibodies can cross-react to neutralise DNASE1L3, impeding DNA clearance and exacerbating inflammation. We conclude by highlighting how these findings underpin the dual role of cfDNA as both a disease mediator and a diagnostic tool and support the ongoing development of IFN-I and pDC-targeting therapies, which show promising clinical relevance. Moreover, we discuss how large-scale validation and standardisation are essential for translating these molecular insights into precision medicine for diverse SLE populations.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1824772","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:29:35Z","timestamp":1782188975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The emerging clinical relevance of cell-free DNA in lupus: from mechanistic insights to therapeutic opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Emily","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Clinical and Biomedical Sciences, University of Exeter","place":["Exeter, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiki","family":"Cano-Gamez","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biomedical Sciences, University of Exeter","place":["Exeter, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.30330","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s43556-024-00217-8","article-title":"Systemic lupus erythematosus: pathogenesis and targeted therapy","volume":"5","author":"Su","year":"2024","journal-title":"Mol BioMed"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2022.100242","article-title":"Circulating DNA fragmentomics and cancer screening","volume":"3","author":"Thierry","year":"2023","journal-title":"Cell Genom"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.001","article-title":"Fragmentomic analysis of circulating tumor DNA-targeted cancer panels","volume":"34","author":"Helzer","year":"2023","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/09612033231226314","article-title":"Clinical algorithm model based on cfDNA to predict SLE disease activity","volume":"33","author":"Wang","year":"2024","journal-title":"Lupus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2024.08.004","article-title":"Genome-wide characterization of extrachromosomal circular DNA in SLE and functional analysis reveal their association with apoptosis","volume":"273","author":"Li","year":"2024","journal-title":"Trans Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003468","article-title":"IgG autoantibodies against deposited C3 inhibit macrophage-mediated apoptotic cell engulfment in systemic autoimmunity","volume":"187","author":"Kenyon","year":"2011","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13041","article-title":"Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection","volume":"15","author":"Jin","year":"2021","journal-title":"Mol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1373\/49.3.495","article-title":"Origin of plasma cell-free DNA after solid organ transplantation","volume":"49","author":"Lui","year":"2003","journal-title":"Clin Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad195","article-title":"The coming of age of liquid biopsy in neuro-oncology","volume":"146","author":"Berzero","year":"2023","journal-title":"Brain"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218062","article-title":"Putative origins of cell-free DNA in humans: A review of active and passive nucleic acid release mechanisms","volume":"21","author":"Grabuschnig","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3390\/biomedicines10112853","article-title":"Cell-free DNA in the pathogenesis and therapy of non-infectious inflammations and tumors","volume":"10","author":"M\u0171zes","year":"2022","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100926","DOI":"10.1016\/j.medj.2025.100926","article-title":"The comings and goings of cell-free DNA: Biological and clinical implications","volume":"7","author":"Malki","year":"2025","journal-title":"Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218810","article-title":"Arg206Cys substitution in DNASE1L3 causes a defect in DNASE1L3 protein secretion that confers risk of systemic lupus erythematosus","volume":"80","author":"Coke","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.39","article-title":"Recent insights into the genetic basis of systemic lupus erythematosus","volume":"10","author":"Moser","year":"2009","journal-title":"Genes Immun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2024.100246","article-title":"Association of autoantibodies with the IFN signature and NETosis in patients with systemic lupus erythematosus","volume":"9","author":"Kaan","year":"2024","journal-title":"J Trans Autoimm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/antib5010002","article-title":"Autoantibodies in SLE: Specificities, isotypes and receptors","volume":"5","author":"Dema","year":"2016","journal-title":"Antibodies"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100903","article-title":"Antibodies against type I IFN: The bad guys self-restrain in systemic lupus erythematosus","volume":"4","author":"Fillatreau","year":"2023","journal-title":"Cell Rep Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Sig Transduc Targ Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2020.01.008","article-title":"The biology of cell-free DNA fragmentation and the roles of DNASE1, DNASE1L3, and DFFB","volume":"106","author":"Han","year":"2020","journal-title":"Am J Hum Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2209852119","article-title":"Epigenetic analysis of cell-free DNA by fragmentomic profiling","volume":"119","author":"Zhou","year":"2022","journal-title":"PNAS"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421126111","article-title":"Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing","volume":"111","author":"Chan","year":"2014","journal-title":"PNAS"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-025-00773-x","article-title":"Cell-free DNA: Features and attributes shaping the next frontier in liquid biopsy","volume":"29","author":"Swarup","year":"2025","journal-title":"Mol Diagn Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092749","article-title":"Liquid biopsy is instrumental for 3PM dimensional solutions in cancer management","volume":"9","author":"Liskova","year":"2020","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101198","article-title":"The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring","volume":"4","author":"Batool","year":"2023","journal-title":"Cell Rep Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad115","article-title":"Deficiency of macrophage-derived Dnase1L3 causes lupus-like phenotypes in mice","volume":"114","author":"Engavale","year":"2023","journal-title":"J Leuk Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1721954","article-title":"Plasma cell-free DNA genome-wide methylation profiling enables detection and activity assessment in systemic lupus erythematosus","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42565","article-title":"Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144561","article-title":"Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics","volume":"6","author":"Sanchez","year":"2021","journal-title":"JCI Insight"},{"key":"B31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41467-023-35959-6","article-title":"DNA methylation analysis explores the molecular basis of plasma cell-free DNA fragmentation","volume":"14","author":"An","year":"2023","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1101\/gr.275426.121","article-title":"Nuclease deficiencies alter plasma cell-free DNA methylation profiles","volume":"31","author":"Han","year":"2021","journal-title":"Genome Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13073-024-01386-5","article-title":"DNA demethylation triggers cell free DNA release in colorectal cancer cells","volume":"16","author":"Pessei","year":"2024","journal-title":"Genome Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2015.2149","article-title":"Genome-wide analysis of 5-hmC in the peripheral blood of systemic lupus erythematosus patients using an hMeDIP-chip","volume":"35","author":"Sui","year":"2015","journal-title":"Int J Mol Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03624-5","article-title":"From concept to clinic: a roadmap for DNA methylation biomarkers in liquid biopsies","volume":"44","author":"Pharo","year":"2025","journal-title":"Oncogene"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-00775-6","article-title":"ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin","volume":"39","author":"Sadeh","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262412127","article-title":"NETosis-related biomarkers in systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: A comparative study","volume":"26","author":"Melamud","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.29252\/ibj.22.5.294","article-title":"Effects of major epigenetic factors on systemic lupus erythematosus","volume":"22","author":"Farivar","year":"2018","journal-title":"Iran BioMed J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"9460","DOI":"10.1038\/s41598-021-88866-5","article-title":"Serial profiling of cell-free DNA and nucleosome histone modifications in cell cultures","volume":"11","author":"Ungerer","year":"2021","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2019.1598759","article-title":"Life and death of circulating cell-free DNA","volume":"20","author":"Kustanovich","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15010109","article-title":"Dynamics and half-life of cell-free DNA after exercise: Insights from a fragment size-specific measurement approach","volume":"15","author":"Yamamoto","year":"2025","journal-title":"Diagnostics"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/1981088a0","article-title":"Fate of injected deoxyribonucleic acid in mice","volume":"198","author":"Tsumita","year":"1963","journal-title":"Nature"},{"key":"B43","article-title":"The clearance and localization of nucleic acids by New Zealand and normal mice","volume":"12","author":"Chused","year":"1972","journal-title":"Clin Exp Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.156.3.1151","article-title":"Blood clearance kinetics and liver uptake of mononucleosomes in mice","volume":"156","author":"Gauthier","year":"1996","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvac180","article-title":"Comparison of single molecule, real-time sequencing and nanopore sequencing for analysis of the size, end-motif, and tissue-of-origin of long cell-free DNA in plasma","volume":"69","author":"Yu","year":"2022","journal-title":"Clin Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/gr.261396.120","article-title":"Detection and characterization of jagged ends of double-stranded DNA in plasma","volume":"30","author":"Jiang","year":"2020","journal-title":"Genome Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12040978","article-title":"Cell-free DNA fragmentomics in liquid biopsy","volume":"12","author":"Ding","year":"2022","journal-title":"Diagnostics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvac050","article-title":"Jagged ends on multinucleosomal cell free DNA serve as a biomarker for nuclease activity and systemic lupus erythematosus","volume":"68","author":"Ding","year":"2022","journal-title":"Clin Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2026.101142","article-title":"Holistic determination of ends of cfDNA molecules","volume":"6","author":"Jiang","year":"2026","journal-title":"Cell Genom"},{"key":"B50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ajhg.2025.12.003","article-title":"Plasma DNA profile associated with DNASE1L3 gene mutations: Clinical observations, relationships to nuclease substrate preference, and in vivo correction","volume":"113","author":"Chan","year":"2025","journal-title":"Am J Hum Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815031116","article-title":"Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA","volume":"116","author":"Serpas","year":"2019","journal-title":"PNAS"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220982120","article-title":"Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs","volume":"120","author":"Zhou","year":"2023","journal-title":"PNAS"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-016-1421-4","article-title":"Cause and consequences of the activated type I interferon system in SLE","volume":"94","author":"Eloranta","year":"2016","journal-title":"J Mol Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"Plasmacytoid dendritic cells: Development, regulation, and function","volume":"50","author":"Reizis","year":"2019","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-016-1465-5","article-title":"Insights from Mendelian interferonopathies: Comparison of CANDLE, SAVI with AGS, monogenic lupus","volume":"94","author":"Kim","year":"2016","journal-title":"J Mol Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: One key to unlocking the mystery of the disease","volume":"6","author":"R\u00f6nnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01287-5","article-title":"DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling","volume":"42","author":"Tusseau","year":"2022","journal-title":"J ClinImmunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.05.014","article-title":"Lupus nephritis patterns and response to type I interferon in patients with DNASE1L3 variants: Report of three cases","volume":"84","author":"Volpi","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.immuni.2020.04.015","article-title":"Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA","volume":"52","author":"Soni","year":"2020","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-024-01696-8","article-title":"Mendelian causes of autoimmunity: The lupus phenotype","volume":"44","author":"Tusseau","year":"2024","journal-title":"J ClinImmunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1172\/jci23025","article-title":"Human lupus autoantibody\u2013 DNA complexes activate DCs through cooperation of CD32 and TLR9","volume":"115","author":"Means","year":"2005","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2021-0023","article-title":"Regulation of cGAS-STING pathway - Implications for systemic lupus erythematosus","volume":"2","author":"Hagiwara","year":"2021","journal-title":"Rheum Immunol Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/art.40002","article-title":"Expression of cyclic GMP\u2010AMP synthase in patients with systemic lupus erythematosus","volume":"69","author":"An","year":"2017","journal-title":"Arth Rheum"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500969","article-title":"Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi\u2013Gouti\u00e8res syndrome","volume":"195","author":"Gray","year":"2015","journal-title":"J Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/imr.12383","article-title":"Endosomal Toll-like receptors in clinically overt and silent autoimmunity","volume":"269","author":"Clancy","year":"2015","journal-title":"Immunol Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2013010026","article-title":"The pathogenesis of lupus nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J Am Sic Nephrol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/art.27700","article-title":"Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease","volume":"62","author":"Sato","year":"2010","journal-title":"Arth Rheum"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01184-8","article-title":"Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus","volume":"21","author":"Goldbach-Mansky","year":"2024","journal-title":"Nat Rev Rheum"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.10.005","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arth Rheum"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"354\u2013","DOI":"10.31138\/mjr.010324.iis","article-title":"Interferon inhibition in SLE: From bench to bedside","volume":"35","author":"Deligeorgakis","year":"2024","journal-title":"Med J Rheum"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel therapies in plaque psoriasis: A review of tyrosine kinase 2 inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermat Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Trans Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417620112","article-title":"Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells","volume":"112","author":"Carrington","year":"2015","journal-title":"PNAS"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-023-01232-y","article-title":"The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation","volume":"30","author":"Liu","year":"2023","journal-title":"Cell Death Differ"},{"key":"B79","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12672-024-01161-3","article-title":"Combination of BCL-2 inhibitors and immunotherapy: A promising therapeutic strategy for hematological Malignancies","volume":"15","author":"Peng","year":"2024","journal-title":"Discov Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132620","article-title":"Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model","volume":"211","author":"Rowland","year":"2014","journal-title":"J Exp Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejr.2017.05.004","article-title":"Antinucleosome antibodies in systemic lupus erythematosus patients: Relation to anti-double stranded deoxyribonucleic acid and disease activity","volume":"40","author":"Abdalla","year":"2017","journal-title":"Egyp J Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-lupus21century.39","article-title":"Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus","volume":"218","author":"Hartl","year":"2021","journal-title":"J Exp Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioteChadv.2015.10.004","article-title":"Modern affinity reagents: Recombinant antibodies and aptamers","volume":"33","author":"Groff","year":"2015","journal-title":"Biotechnol Adv"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41467-023-37083-x","article-title":"Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus","volume":"14","author":"Gomez-Ba\u00f1uelos","year":"2023","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102900","article-title":"Evidence for charge-based mimicry in anti dsDNA antibody generation","volume":"132","author":"Bruschi","year":"2022","journal-title":"J Autoimmun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000382","article-title":"Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus","volume":"7","author":"Han","year":"2020","journal-title":"Lupus Sci Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B88","volume-title":"A phase 1 randomized, placebo-controlled, blinded, multiple ascending dose study to evaluate VIB7734 in systemic lupus erythematosus, cutaneous lupus erythematosus, Sj\u00f6gren's syndrome, systemic sclerosis, polymyositis, and dermatomyositis","year":"2020"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.968323","article-title":"Emerging therapies in cutaneous lupus erythematosus","volume":"9","author":"Sprow","year":"2022","journal-title":"Front Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1055\/a-2444-3422","article-title":"Neutrophil extracellular traps (NETs) as a potential target for anti-aging: Role of therapeutic apheresis","volume":"57","author":"Jarzebska","year":"2025","journal-title":"Horm Metabol Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25887","article-title":"The role of belimumab in systemic lupus erythematosis: A systematic review","volume":"14","author":"Joy","year":"2022","journal-title":"Cureus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1824772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:29:36Z","timestamp":1782188976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1824772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2026.1824772"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1824772","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1824772"}}